- Home
- GDTC vs TPST Comparison
GDTC vs TPST Comparison
Compare GDTC & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDTC | TPST |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 11.1M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GDTC | TPST |
|---|---|---|
| Price | $1.06 | $2.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 27.0K | ★ 53.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $0.60 |
| 52 Week High | $3.68 | $12.22 |
Technical Indicators
Market Signals| Indicator | GDTC | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 38.25 |
| Support Level | $0.96 | $2.14 |
| Resistance Level | $1.25 | $2.52 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 43.53 | 25.32 |
Price Performance
Historical ComparisonAbout GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.